Estrid V Hgdall

List of Publications by Citations

Source: https://exaly.com/author-pdf/9426346/estrid-v-hogdall-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 173
 6,698
 43
 77

 papers
 citations
 h-index
 g-index

 179
 7,988
 5.8
 5.12

 ext. papers
 ext. citations
 avg, IF
 L-index

| # | Paper | IF | Citations |
|-----|---|--------------------|-----------|
| 173 | Genetic and Functional Drivers of Diffuse Large BICell Lymphoma. <i>Cell</i> , 2017 , 171, 481-494.e15 | 56.2 | 499 |
| 172 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 382-90 | 27.4 | 427 |
| 171 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2 | 36.3 | 422 |
| 170 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 362-70, 370e1-2 | 36.3 | 267 |
| 169 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology, The</i> , 2013 , 14, 853-62 | 21.7 | 248 |
| 168 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2901-7 | 2.2 | 200 |
| 167 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691 | 36.3 | 190 |
| 166 | The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. <i>Cancer Research</i> , 2006 , 66, 10630-6 | 10.1 | 157 |
| 165 | MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. <i>Gynecologic Oncology</i> , 2013 , 128, 300-8 | 4.9 | 146 |
| 164 | The diagnostic value of PET/CT for primary ovarian cancera prospective study. <i>Gynecologic Oncology</i> , 2007 , 105, 145-9 | 4.9 | 128 |
| 163 | Sample handling for mass spectrometric proteomic investigations of human sera. <i>Analytical Chemistry</i> , 2005 , 77, 5114-23 | 7.8 | 127 |
| 162 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013 , 4, 1628 | 17.4 | 124 |
| 161 | Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1812-7 | 2.2 | 123 |
| 160 | Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. <i>International Journal of Epidemiology</i> , 2013 , 42, 579-89 | 7.8 | 122 |
| 159 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811 | 5.8 | 121 |
| 158 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 652-7 | 12.9 | 107 |
| 157 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052- | 6 7 4·4 | 104 |

(2011-2017)

| 1 | .56 | Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. <i>European Journal of Cancer</i> , 2017 , 70, 75-82 | 7.5 | 86 | |
|---|-----|---|------|----|--|
| 1 | -55 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013 , 4, 1627 | 17.4 | 85 | |
| 1 | -54 | Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1160-6 | 4 | 82 | |
| 1 | -53 | Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. <i>Archives of Internal Medicine</i> , 2004 , 164, 2253-9 | | 81 | |
| 1 | .52 | BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. <i>Clinical Cancer Research</i> , 2008 , 14, 3761-7 | 12.9 | 77 | |
| 1 | .51 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 1619-1630 | 7.8 | 77 | |
| 1 | .50 | High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. <i>Apmis</i> , 2011 , 119, 663-73 | 3.4 | 71 | |
| 1 | 49 | Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , 2013 , 24, 989-1004 | 2.8 | 69 | |
| 1 | 48 | BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. <i>OncoImmunology</i> , 2012 , 1, 1476-1483 | 7.2 | 68 | |
| 1 | 47 | Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 847, 30-7 | 3.2 | 61 | |
| 1 | 46 | Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. <i>Cellular Oncology (Dordrecht)</i> , 2014 , 37, 215-27 | 7.2 | 56 | |
| 1 | 45 | Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 134-7 | 8.7 | 55 | |
| 1 | 44 | miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. <i>PLoS ONE</i> , 2014 , 9, e99886 | 3.7 | 54 | |
| 1 | 43 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675 | 17.4 | 53 | |
| 1 | .42 | Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. <i>Pancreas</i> , 2012 , 41, 759-66 | 2.6 | 52 | |
| 1 | 41 | Cancer antigen 125 and prognosis. Current Opinion in Obstetrics and Gynecology, 2008, 20, 4-8 | 2.4 | 51 | |
| 1 | 40 | HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2285- | 95 | 49 | |
| 1 | 39 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011 , 128, 2063-74 | 7.5 | 49 | |

| 138 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015 , 24, 5955-64 | 5.6 | 48 |
|-----|---|-------------------|----|
| 137 | HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2013 , 92, 131 | 3 ² 22 | 48 |
| 136 | Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 798-803 | 4 | 46 |
| 135 | The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , 2015 , 123, 108-15 | 3.4 | 45 |
| 134 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. <i>Clinical Cancer Research</i> , 2011 , 17, 3742-50 | 12.9 | 45 |
| 133 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 884-95 | 7.8 | 45 |
| 132 | Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. <i>American Journal of Epidemiology</i> , 2017 , 185, 8-20 | 3.8 | 44 |
| 131 | Bacterial infection as a likely cause of adverse reactions to polyacrylamide hydrogel fillers in cosmetic surgery. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1438-44 | 11.6 | 44 |
| 130 | Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 600-4 | 3.5 | 42 |
| 129 | SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. <i>Gynecologic Oncology</i> , 2013 , 129, 298-303 | 4.9 | 39 |
| 128 | Human papillomavirus in head and neck squamous cell carcinoma of unknown primary is a common event and a strong predictor of survival. <i>PLoS ONE</i> , 2014 , 9, e110456 | 3.7 | 37 |
| 127 | Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: AlPopulation-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1900-19 | 07:e2 | 34 |
| 126 | Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. <i>PLoS ONE</i> , 2009 , 4, e5983 | 3.7 | 33 |
| 125 | Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. <i>Acta Oncolgica</i> , 2011 , 50, 415-9 | 3.2 | 31 |
| 124 | Assessment of hepatocyte growth factor in ovarian cancer mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1638-48 | 4 | 30 |
| 123 | Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. <i>Apmis</i> , 2009 , 117, 518-25 | 3.4 | 29 |
| 122 | Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). <i>Gynecologic Oncology</i> , 2016 , 142, 50-53 | 4.9 | 26 |
| 121 | MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. <i>BMC Cancer</i> , 2015 , 15, 1024 | 4.8 | 26 |

(2018-2015)

| 120 | The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. <i>Gynecologic Oncology</i> , 2015 , 136, 205-11 | 4.9 | 26 |
|-----|--|------|----|
| 119 | Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 1163-9 | 3.5 | 26 |
| 118 | Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. <i>PLoS ONE</i> , 2018 , 13, e0207319 | 3.7 | 26 |
| 117 | Clinical implications of intestinal stem cell markers in colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 63-71 | 3.8 | 25 |
| 116 | Molecular signatures of thyroid follicular neoplasia. <i>Endocrine-Related Cancer</i> , 2010 , 17, 691-708 | 5.7 | 25 |
| 115 | Current status on microRNAs as biomarkers for ovarian cancer. <i>Apmis</i> , 2016 , 124, 337-55 | 3.4 | 25 |
| 114 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015 , 21, 5264-76 | 12.9 | 24 |
| 113 | Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , 2013 , 13, 28 | 4.8 | 23 |
| 112 | Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. <i>Cancer Causes and Control</i> , 2013 , 24, 1459-64 | 2.8 | 23 |
| 111 | Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. <i>Cancer Causes and Control</i> , 2008 , 19, 469-79 | 2.8 | 23 |
| 110 | Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1822-30 | 4 | 22 |
| 109 | Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 940-52 | 3.1 | 22 |
| 108 | MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 22 |
| 107 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014 , 133, 481-97 | 6.3 | 21 |
| 106 | miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 207 | 5.3 | 21 |
| 105 | Use of dairy products, lactose, and calcium and risk of ovarian cancer - results from a Danish case-control study. <i>Acta Oncolgica</i> , 2012 , 51, 454-64 | 3.2 | 21 |
| 104 | PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. <i>Oncotarget</i> , 2015 , 6, 32266-78 | 3.3 | 21 |
| 103 | Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. <i>Oncolmmunology</i> , 2018 , 7, e1412029 | 7.2 | 21 |

| 102 | Risk factors for brain metastases in patients with metastatic colorectal cancer. <i>Acta Oncològica</i> , 2017 , 56, 639-645 | 3.2 | 20 |
|-----|--|-----------------|----|
| 101 | Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. <i>Modern Pathology</i> , 2018 , 31, 1211-12 | 25 ⁸ | 20 |
| 100 | Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011 , 6, e20703 | 3.7 | 20 |
| 99 | History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. <i>Cancer Causes and Control</i> , 2017 , 28, 469-486 | 2.8 | 19 |
| 98 | Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?. <i>Molecular and Clinical Oncology</i> , 2019 , 10, 323-330 | 1.6 | 19 |
| 97 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017 , 116, 524-535 | 8.7 | 18 |
| 96 | Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017 , 140, 2422-2435 | 7.5 | 18 |
| 95 | The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. <i>Cancer Cytopathology</i> , 2018 , 126, 275-281 | 3.9 | 18 |
| 94 | Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. <i>Apmis</i> , 2006 , 114, 359-63 | 3.4 | 18 |
| 93 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016 , 135, 741-56 | 6.3 | 18 |
| 92 | The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016 , 41, 71-9 | 2.8 | 17 |
| 91 | SOX9 expression predicts relapse of stage II colon cancer patients. <i>Human Pathology</i> , 2016 , 52, 38-46 | 3.7 | 17 |
| 90 | High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. <i>Modern Pathology</i> , 2014 , 27, 1590-8 | 9.8 | 17 |
| 89 | Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. <i>Acta Oncolgica</i> , 2015 , 54, 1144-51 | 3.2 | 17 |
| 88 | Identification of bacteria using two degenerate 16S rDNA sequencing primers. <i>Microbiological Research</i> , 1999 , 154, 23-6 | 5.3 | 17 |
| 87 | A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. <i>PLoS ONE</i> , 2012 , 7, e33100 | 3.7 | 17 |
| 86 | Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 82-90 | 3.5 | 17 |
| 85 | MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie</i> | 5.1 | 16 |

| 84 | KRAS and BRAF mutations in anal carcinoma. <i>Apmis</i> , 2015 , 123, 53-9 | 3.4 | 16 |
|----|---|---------------------|------------------|
| 83 | Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2012 , 91, 1094-102 | 3.8 | 16 |
| 82 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401 | 4.9 | 15 |
| 81 | A novel monoclonal antibody to a defined peptide epitope in MUC16. <i>Glycobiology</i> , 2015 , 25, 1172-82 | 5.8 | 15 |
| 80 | Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. <i>Acta Oncologica</i> , 2018 , 57, 1057-1062 | 3.2 | 15 |
| 79 | A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. <i>Tumor Biology</i> , 2016 , 37, 12619-12626 | 2.9 | 15 |
| 78 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320 | 6.4 | 14 |
| 77 | Intra-tumor heterogeneity of microRNA-92a, microRNA-375 and microRNA-424 in colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2016 , 100, 125-31 | 4.4 | 14 |
| 76 | Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics - Clinical Applications, 2010 , 4, 304-14 | 3.1 | 14 |
| 75 | Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017 , 28, 459-468 | 2.8 | 13 |
| 74 | Risk of ovarian cancer in women with first-degree relatives with cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2009 , 88, 449-56 | 3.8 | 13 |
| 73 | Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. <i>PLoS ONE</i> , 2019 , 14, e0225249 | 3.7 | 13 |
| 72 | Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , 2015 , 137, 2000-6 | 7.5 | 12 |
| 71 | Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion. <i>Gene</i> , 2013 , 517, 72-81 | 3.8 | 12 |
| 70 | Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. <i>Analytical Chemistry</i> , 2009 , 81, 190 | 17 7 183 | 12 |
| 69 | Gene expression profiles as prognostic markers in women with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1205-13 | 3.5 | 12 |
| 68 | Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017 , 116, 1223-1228 | 8.7 | 11 |
| 67 | Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study. <i>Pathology Research and Practice</i> , 2018 , 214, 12 | 73-428 | 31 ¹¹ |

| 66 | History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , 2017 , 117, 1063-1069 | 8.7 | 11 |
|----|---|------|----|
| 65 | HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. <i>Apmis</i> , 2016 , 124, 1038-1045 | 3.4 | 10 |
| 64 | Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. <i>Human Pathology</i> , 2018 , 80, 231-238 | 3.7 | 10 |
| 63 | The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2002 , 22, 385-7 | 3.2 | 10 |
| 62 | Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. <i>PLoS ONE</i> , 2012 , 7, e30997 | 3.7 | 10 |
| 61 | Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. <i>Contemporary Clinical Trials Communications</i> , 2017 , 8, 167-174 | 1.8 | 9 |
| 60 | The prevalence of EBV and CMV DNA in epithelial ovarian cancer. <i>Infectious Agents and Cancer</i> , 2019 , 14, 7 | 3.5 | 9 |
| 59 | Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. <i>PLoS ONE</i> , 2017 , 12, e0174300 | 3.7 | 9 |
| 58 | Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2016 , 101, 187-196 | 4.4 | 9 |
| 57 | Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncology Letters, 2016, 11, 393-398 | 2.6 | 9 |
| 56 | Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. <i>BMC Cancer</i> , 2018 , 18, 640 | 4.8 | 9 |
| 55 | Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2039-46 | 1.9 | 9 |
| 54 | Sample handling for mass spectrometric proteomic investigations of human urine. <i>Proteomics - Clinical Applications</i> , 2008 , 2, 1184-93 | 3.1 | 9 |
| 53 | RNA profiles reveal signatures of future health and disease in pregnancy <i>Nature</i> , 2022 , | 50.4 | 9 |
| 52 | Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1348-55 | 4 | 9 |
| 51 | Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1804-1812 | 3.5 | 8 |
| 50 | Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma. <i>Apmis</i> , 2015 , 123, 298-304 | 3.4 | 8 |
| 49 | Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 780-90 | 4 | 8 |

(2016-2018)

| 48 | Effect of inhibition of CBP-coactivated Exatenin-mediated Wnt signalling in uremic rats with vascular calcifications. <i>PLoS ONE</i> , 2018 , 13, e0201936 | 3.7 | 8 | |
|----|---|-----|---|--|
| 47 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 2023-35 | 5.9 | 8 | |
| 46 | History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1470-1473 | 4 | 8 | |
| 45 | HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2015 , 94, 1262-8 | 3.8 | 8 | |
| 44 | Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the TMALOVATovarian cancer study. <i>Apmis</i> , 2013 , 121, 1177-86 | 3.4 | 8 | |
| 43 | Genome-wide association study for ovarian cancer susceptibility using pooled DNA. <i>Twin Research and Human Genetics</i> , 2012 , 15, 615-623 | 2.2 | 8 | |
| 42 | Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2019 , 39, 2475-2482 | 2.3 | 7 | |
| 41 | Evidence of No Association Between Human Papillomavirus and Breast Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 209 | 5.3 | 7 | |
| 40 | High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1312-1324 | 7 | 7 | |
| 39 | Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. <i>International Journal of Breast Cancer</i> , 2013 , 2013, 368731 | 2.3 | 7 | |
| 38 | Next Generation Sequencing Technology in the Clinic and Its Challenges. <i>Cancers</i> , 2021 , 13, | 6.6 | 7 | |
| 37 | Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the TMalovaTovarian cancer study. <i>Apmis</i> , 2015 , 123, 401-9 | 3.4 | 6 | |
| 36 | Serum tetranectin is a significant prognostic marker in ovarian cancer patients. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2010 , 89, 190-8 | 3.8 | 6 | |
| 35 | DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. <i>Endoscopic Ultrasound</i> , 2020 , 9, 37-44 | 3.6 | 6 | |
| 34 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020 , 158, 702-709 | 4.9 | 5 | |
| 33 | (GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , 2016 , 11, e0168210 | 3.7 | 5 | |
| 32 | Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. <i>Oncotarget</i> , 2017 , 8, 108213-108222 | 3.3 | 5 | |
| 31 | Approaches to the detection of ovarian cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016 , 245, S49-53 | 2 | 4 | |

| 30 | A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1535-8 | 3.5 | 4 |
|----|--|-----|---|
| 29 | Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011 , 6, e19642 | 3.7 | 4 |
| 28 | Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods. <i>Biopreservation and Biobanking</i> , 2019 , 17, 562-569 | 2.1 | 4 |
| 27 | The somatic mode: doing good in targeted cancer therapy. <i>New Genetics and Society</i> , 2021 , 40, 178-198 | 1.9 | 4 |
| 26 | Serum YKL-40 and uterine artery Doppler a prospective cohort study, with focus on preeclampsia and small-for-gestational-age. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2014 , 93, 817-24 | 3.8 | 3 |
| 25 | Oncomine©comprehensive Assay v3 vs. Oncomine©comprehensive Assay Plus. <i>Cancers</i> , 2021 , 13, | 6.6 | 3 |
| 24 | Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. <i>Apmis</i> , 2020 , 128, 3-9 | 3.4 | 3 |
| 23 | Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0100121 | 9.7 | 3 |
| 22 | The prognostic value of polycomb group protein B-cell-specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients. <i>Apmis</i> , 2016 , 124, 541-6 | 3.4 | 2 |
| 21 | Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2013 , 92, 721-6 | 3.8 | 2 |
| 20 | Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. <i>Cancers</i> , 2021 , 13, | 6.6 | 2 |
| 19 | The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review). <i>International Journal of Molecular Medicine</i> , 2019 , 44, 1599-1608 | 4.4 | 2 |
| 18 | Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1034-1042 | 3.5 | 2 |
| 17 | Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. <i>Scientific Reports</i> , 2021 , 11, 5438 | 4.9 | 2 |
| 16 | Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. <i>Reproductive Sciences</i> , 2021 , 28, 757-765 | 3 | 2 |
| 15 | Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. <i>Gynecologic Oncology</i> , 2010 , 117, 446-50 | 4.9 | 1 |
| 14 | Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. <i>Apmis</i> , 2020 , 128, 573-582 | 3.4 | 1 |
| 13 | Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 507-514 | 5.1 | 1 |

LIST OF PUBLICATIONS

| 12 | MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021 , 16, e0252401 | 3.7 | 1 |
|----|---|--------------------|-----|
| 11 | Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021 , 16, e0255142 | 3.7 | 1 |
| 10 | Incidents in Molecular Pathology: Frequency and Causes During Routine Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 1270-1279 | 5 | 1 |
| 9 | Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021 , 522, 152-157 | 6.2 | 1 |
| 8 | DNA Methylation in Ovarian Tumors-a Comparison Between Fresh Tissue and FFPE Samples. <i>Reproductive Sciences</i> , 2021 , 28, 3212-3218 | 3 | О |
| 7 | Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019 , 27, 631-636 | 1.9 | O |
| 6 | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) <i>Molecular and Clinical Oncology</i> , 2022 , 16, 29 | 1.6 | О |
| 5 | Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , 2015 , 43, 534-6 | 3.1 | |
| 4 | Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1028-31 | 4 | |
| 3 | The nationwide Danish CancerBiobank: Future possibilies <i>Journal of Clinical Oncology</i> , 2014 , 32, e221 | 96 <u>>e</u> 22 | 196 |
| 2 | Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan <i>Journal of Clinical Oncology</i> , 2016 , 34, e15115-e15115 | 2.2 | |
| 1 | FP375EFFECT OF WNT-INHIBITION ON ESTABLISHED VASCULAR CALCIFICATION IN UREMIC RATS. Nephrology Dialysis Transplantation, 2018 , 33, i159-i159 | 4.3 | |